Literature DB >> 3324963

Correction for bacterial loss in in vitro dilution models.

C A White1, R D Toothaker, A L Smith, J T Slattery.   

Abstract

A new method to correct for bacteria lost to dilution in in vitro kinetic models is presented which includes the influence of the stationary bacterial growth phase. The method imposes an upper limit on bacterial density, in contrast to previous methods.

Entities:  

Mesh：

Year:  1987        PMID： 3324963      PMCID： PMC175055          DOI： 10.1128/AAC.31.11.1859

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics.

Authors:  T Murakawa; H Sakamoto; T Hirose; M Nishida
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

2.  New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.

Authors:  S Grasso; G Meinardi; I de Carneri; V Tamassia
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

3.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

4.  Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro.

Authors:  A U Gerber; P Wiprächtiger; U Stettler-Spichiger; G Lebek
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226
  4 in total
  7 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

3.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

4.  In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli.

Authors:  C A White; R D Toothaker; A L Smith; J T Slattery
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 5.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Authors:  Pavan K Vaddady; Richard E Lee; Bernd Meibohm
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

6.  Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.

Authors:  B A Nies
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

7.  Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.

Authors:  Johan W Mouton; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.